重藥控股(000950.SZ):重藥股份擬向重藥九隆提供財務資助5772萬元
格隆匯5月19日丨重藥控股(000950.SZ)公佈,根據戰略發展規劃,公司着力培育中藥板塊,將其打造成較強的利潤貢獻板塊。生產端的重點實施載體之一為重藥九隆,該公司為公司控股子公司重藥股份與合肥三九合資組建而成,其中重藥股份持股49%,合肥三九持股51%。利用重藥九隆這一載體,通過協同華潤三九體系中藥資源,以構建公司中藥飲片供應鏈產銷聯動體系。
目前重藥九隆處於工廠建設階段,由於現項目建設資金全部來源於實繳資金,不足以滿足項目建設需要,重藥九隆申請向股東雙方同比例借款,借款總額1.178億元,其中向重藥股份借款5772萬元,向合肥華潤三九中醫藥發展有限公司借款6008萬元,根據工程建設及付款進度分次到位。
本次申請借款期限為三年(自實際提款日起算),利率按不低於4.6%/年收取,重藥九隆股東雙方執行相同利率。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.